Staining of the prostate cancer progression panel with this validated antibody revealed a significant decrease in average CSK reactivity in metastatic prostate cancer and CRPCs relative to primary prostate cancers (Figure 5B, Supplementary Figure S5B). This evidence concerns the gene CSK and prostate cancer.